Bridgebio Email Format

Biotechnology Research
501-1,000 employees
Palo Alto, CA, USA

BridgeBio is a biotechnology company focused on discovering and developing transformative medicines for patients living with genetic diseases and cancers.

Find contacts at Bridgebio

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@bridgebio.com

Company Overview

Industry
Biotechnology Research
Founded
2014
Headquarters
Palo Alto, CA, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Key Executives
Neil Kumar (Chief Executive Officer), Thomas Trimarchi, Ph.D. (President and Chief Financial Officer), Matt Outten (Chief Commercial Officer)

Tech Stack

Databricks

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Bridgebio?

Bridgebio uses the first.last format, so Jane Smith would be jane.smith@bridgebio.com.

What is Bridgebio's first commercially approved product?

Bridgebio's first commercially approved product is Attruby (acoramidis), a medicine for transthyretin amyloid cardiomyopathy that received FDA approval in November 2024 and has since been approved in the U.S., EU, Japan, the UK, Switzerland, and Brazil.

How many employees does Bridgebio have?

Bridgebio has approximately 910 employees. You can use Clay to build a targeted list of Bridgebio contacts and verify their details before outreach.

Who leads Bridgebio as CEO?

Neil Kumar is the Chief Executive Officer of Bridgebio. The company's leadership team also includes Thomas Trimarchi, Ph.D. as President and Chief Financial Officer, and Matt Outten as Chief Commercial Officer.

What genetic disease areas does Bridgebio's pipeline focus on in 2026?

Bridgebio's 2026 pipeline spans transthyretin amyloidosis, limb-girdle muscular dystrophy, autosomal dominant hypocalcemia, achondroplasia, and hypochondroplasia, with multiple NDA submissions planned or already filed with the FDA for rare genetic conditions.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles